Mesoblast eyes AMD indication with new stem cell therapy trial
This article was originally published in Clinica
Mesoblast will be evaluating its stem cell therapy in eye disease for the first time, after being cleared to start a Phase II trial of its off-the-shelf technology in age-related macular degeneration (AMD). The trial will enrol 18 patients in Singapore with neovascular, or wet, AMD, which is thought to account for around 90% of blindness in the elderly.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.